Nurix Therapeutics Inc (NRIX)
$25.77
$-0.01
(-0.04%)
As on 01-Sep-2026 13:35EDT
Market cap
$2,720 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
6.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
103,781,683
6 Years Aggregate
CFO
$-356.69 Mln
EBITDA
$-515.71 Mln
Net Profit
$-501.56 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nurix Therapeutics Inc (NRIX)
| 35.8 | 11.0 | 45.1 | 175.9 | 44.7 | -4.4 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Nurix Therapeutics Inc (NRIX)
| 0.7 | 81.7 | -6.0 | -62.1 | -12.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nurix Therapeutics Inc (NRIX)
|
25.8 | 2,720.1 | 36.8 | -341.4 | -929.2 | -72.5 | -- | 6.9 |
| 82.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.7 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.8 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 361.3 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 536.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 587.1 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The... company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California. Read more
-
CEO, President & Director
Dr. Arthur T. Sands M.D., Ph.D.
-
CEO, President & Director
Dr. Arthur T. Sands M.D., Ph.D.
-
Headquarters
Brisbane, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nurix Therapeutics Inc (NRIX)
What is the current share price of Nurix Therapeutics Inc (NRIX) Today?
The share price of Nurix Therapeutics Inc (NRIX) is $25.77 (NASDAQ) as of 01-Sep-2026 13:35 EDT. Nurix Therapeutics Inc (NRIX) has given a return of 44.73% in the last 3 years.
What is the current PB & PE ratio of Nurix Therapeutics Inc (NRIX)?
Since, TTM earnings of Nurix Therapeutics Inc (NRIX) is negative, P/E ratio is not available.
The P/B ratio of Nurix Therapeutics Inc (NRIX) is 6.93 times as on 28-Aug-2026, a 34 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
What is the 52 Week High and Low of Nurix Therapeutics Inc (NRIX)?
The 52-week high and low of Nurix Therapeutics Inc (NRIX) are Rs 28.23 and Rs 8.20 as of 02-Sep-2026.
What is the market cap of Nurix Therapeutics Inc (NRIX)?
Nurix Therapeutics Inc (NRIX) has a market capitalisation of $ 2,720 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nurix Therapeutics Inc (NRIX)?
Before investing in Nurix Therapeutics Inc (NRIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.